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A B S T R A C T
Purpose: To examine the efﬁcacy and safety proﬁle of antiepileptic repetitive transcranial magnetic
stimulation (rTMS) for refractory status epilepticus (RSE) in the intensive care unit (ICU) setting. In
addition, hypothetical concerns about electrical interference of rTMS with ICU equipment have been
previously raised.
Methods: We describe two cases of RSE treated with rTMS in the ICU.
Results: In one case, rTMS contributed to decreased seizure frequency; in the second case, rTMS
transiently decreased seizure frequency. In both cases, rTMS was safe and did not interfere with the
functioning of the ICU equipment.
Conclusion: rTMS is a potential therapy for RSE when conventional therapies have failed. Future studies
should investigate the efﬁcacy of various rTMS stimulation parameters, safety issues, and bioengineering
considerations in the ICU setting.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Approximately 15–20% of cases of status epilepticus (SE) will
become refractory.1,2 Seizures which have persisted over 120 min
are considered refractory status epilepticus (RSE), which often
requires intensive care for continuous intravenous antiepileptic
drugs (AEDs), general anesthesia, and/or cardiorespiratory sup-
port3. Given its life-threatening nature, when conventional
treatments fail, experimental pharmacologic and non-pharmaco-
logic therapies are attempted. Most of the relevant clinical
literature on treatment of RSE consists of case reports and series,
with few controlled trials and systematic reviews.3
Repetitive transcranial magnetic stimulation (rTMS) is a
potential therapy for RSE. rTMS is a non-invasive technique where
pulsed intracranial electrical current is induced by electromagnetic
induction. In most subjects, a continuous train of low frequency* Corresponding author at: Boston Children’s Hospital, Harvard Medical School,
300 Longwood Avenue, CLS 14/Fegan 9, Boston, MA 02115 USA;
Tel.: +011 1 617 355 8071.
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http://dx.doi.org/10.1016/j.seizure.2013.06.014(1 Hz) pulses results in cortical suppression, while trains of high
frequency (5 Hz) pulses result in facilitation of cortical excitabil-
ity.4,5
Several case reports describe low-frequency rTMS application
in medication-refractory focal epilepsy or RSE in non-ICU patients,
with mixed results.6–8 rTMS is well-tolerated by patients with
epilepsy, without reports of seizure exacerbation9 and seizure
suppression can be achieved by low frequency rTMS.7 The efﬁcacy
and safety proﬁle of antiepileptic rTMS in the ICU is poorly
understood. Only one prior successful case of rTMS for RSE in the
ICU has been reported.10 Hypothetical concerns about interference
with ICU electronic equipment may also limit clinical use and
warrant further exploration.
We present two patients with focal RSE managed in the ICU. In
both cases, a clinical decision to treat the ongoing seizures with
rTMS was made. rTMS was delivered by physicians experienced in
the clinical application of rTMS. Informed consent was obtained.
2. Patient 1
A 46 year old patient with intractable epilepsy since childhood
presented with increasing seizure frequency. His baseline of 2–3vier Ltd. All rights reserved.
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prior to admission. Typical seizures included brief drop attacks,
staring with body stiffening and left arm elevation, and secondarily
generalized convulsions. A right temporo-parietal lobectomy in
1991 and vagus nerve stimulator (VNS), placed in 1998 and
deactivated in 2001, were ineffective. Multiple AEDs were tried
over the years (Table 1).
On admission, he was on phenobarbital, phosphenytoin,
pregabalin, and lamotrigine (Table 1). Physical exam showed
drowsiness and baseline mild left hemiparesis. Lumbar puncture
was unremarkable. An MRI showed right parieto-occipital cortical
thickening with mildly restricted diffusion, remote surgical
resection and chronic right frontotemporal encephalomalacia.
After intravenous lorazepam, phosphenytoin and phenobarbi-
tal were ineffective, he was intubated and started on a midazolam
infusion. Because of resulting bradycardia and persistent agitation,
he was switched to propofol. While the number of seizures
declined, the patient still experienced 30–40 electrographic
seizures daily. These were characterized by rhythmic, sharp alpha
frequency activity over the right frontotemporal region, with
frequent bilateral spread, lasting up to several minutes each,
without clinical correlate.
On day 4, due to risk of propofol infusion syndrome,
pentobarbital infusion was initiated (Table 1). As pentobarbital
was weaned, frequent electrographic seizures recurred. The
ketogenic diet was initiated on day 6 but stopped on day 9 due
to developing ileus. With attempted pentobarbital wean on day 16,
his seizure frequency increased again (Fig. 1), requiring a further
moderate increase in his standing AEDs.
Finally, the clinical team decided to administer rTMS on day 21
over the right centrotemporal region. Neurologically, the patient
was intubated and sedated. Prior to starting rTMS, the stimulating
coil was discharged repeatedly at 100% machine output (MO) in
mid-air to ensure absence of interference with the ICU monitoring
equipment. Motor threshold (MT) could not be determined due to
the patient’s signiﬁcant peripheral edema. Therefore, the team
decided to stimulate at 70% MO.11 Stimulation was applied with a
ﬁgure-of-8 coil (Cool B56, Tonica, Denmark) centered over
electrodes C4/T4 with handle oriented toward vertex. A single
train at 1 Hz was applied for 20 min with the C4/T4 electrodesTable 1
Therapies attempted during hospitalization to stop focal status epilepticus.
Patient Therapy Dosage 
Patient 1 Phenobarbital Titrated to high the
Pregabalin 150 mg tid 
Lamotrigine 200 mg tid 
Phosphenytoin 150 mg tid 
Lacosamide 200 mg bid 
Levetiracetam 2000 mg bid 
Midazolam drip 0.1 mg/kg/h 
Propofol drip >10 mg/kg/h 
Pentobarbital drip Titrated to burst su
Ketogenic diet Titrated to urine ke
TMS 1 Hz, 20 min, 70% M
Patient 2 Lamotrigine 200 mg/300 mg 
Levetiracetam 2000 mg qid 
Felbatol 1500 mg tid 
Lorazepam 2 mg every 4 h and 
Lacosamide 250 mg bid 
VNS Baseline settings an
TMS 1 Hz, 30 min, 100% 
Prior to hospitalization, patient 1 had a temporo-parietal lobectomy in 1991, a vagus nerv
therapies over the years, Including carbamazepine, valproic acide, tiagabine, levetirace
Patient 2 had also previously received a sensorimotor corticectomy in 1993, and vagal n
including tranxene, phenobarbital, carbamazepine, valproic acid, gabapentin, and pheny
qid (four times a day). d (days), mg (milligrams), kg (kilograms), h (hour), prn (as clinremoved. The patient tolerated the stimulation uneventfully. ICU
electronic equipment, including clinical computer console, vital
signs monitor, ventilator, medication pump, feeding pump, bed,
pneumatic boot machine, and EEG remained operational during
neurostimulation.
In the 72 h prior to rTMS, a median of 22 electrographic seizures
per day (range 5–22), and a median of 75 spike detections (range
57–86) were recorded. This decreased to 9 seizures per day (range
3–11) and 17 spike detections (range 15–355) in the 72 h following
rTMS, which allowed pentobarbital and phenobarbital doses to be
weaned and decreased, respectively (Fig. 1). EEG background and
mental status gradually improved and the patient was discharged
to a rehabilitation center on day 47.
3. Patient 2
A 51 year old man with depression, sleep apnea, and focal
epilepsy with dyscognitive features and secondary generalization
presented with frequent focal seizures. Seizures originated from
the left mid and posterior temporal region and were characterized
by right arm and leg clonic movements lasting several minutes. His
seizures continued despite a sensorimotor corticectomy in 1993,
VNS placement in 1998, and numerous AED trials (Table 1).
On presentation, he experienced 4–5 seizures daily (lasting 20–
70 min/day). He was taking lamotrigine, levetiracetam, felbamate,
and lorazepam (Table 1) and had received multiple doses of
lorazepam and clonazepam without beneﬁt before hospital arrival.
Admission exam demonstrated increased right-sided hemiparesis
and unsteady gait. Addition of lacosamide, high-dose lorazepam,
higher-dose levetiracetam, and frequent VNS magnet activations
were ineffective. He was transferred to the ICU for respiratory
monitoring but was never intubated. As his seizures were clinically
obvious, he was not continuously monitored on EEG.
On hospital day 9 there was a clinical decision to administer
rTMS. The patient’s VNS was deactivated prior to TMS start. A
single 30 min 1 Hz rTMS train was delivered over the left
sensorimotor cortex. Stimulation intensity was 100% hand MT
as determined by visual inspection. The stimulation device and
orientation was identical to that in case #1. The patient tolerated
rTMS without complication. Again, the electronic equipmentDays of hospitalization
rapeutic level 1-discharge (47 d)
1–12; 19-discharge
1–12; 19-discharge
1-discharge
12-discharge
13-discharge
1–2
2–4
ppression 4–22 (attempted wean on day 16)
toacidosis 6–9
O 21
1-discharge (22 d)
1-discharge
1-discharge
prn 1-discharge
2-discharge
d prn magnetic activation 1-discharge
MT 9
e stimulator placed in 1998, and had been tried on multiple antiepileptic medication
tam, zonisamide, topiramate, felbamate, gabapentin, lacosamide, and ruﬁnamide.
erve stimulator in 1993, and had been tried on multiple antiepileptic medications,
toin prior to hospitalization. Abbreviations. bid (twice a day), tid (three times a day),
ically indicated), MT (motor threshold), TMS (transcranial magnetic stimulation).
Fig. 1. ICU course of Patient Number 1. On admission, the patient experienced between 40–50 seizures daily (blue line, daily seizure frequency). After the initiation of
pentobarbital sedation on day 4, the patient’s seizure frequency abated but did not completely discontinue. After developing ileus thought likely secondary to pentobarbital,
there was an attempt to wean the pentobarbital on day 16 with resulting increased seizure frequency. His intravenous AEDS were further increased with modest
improvement. On day 21, TMS was administered in the ICU over the seizure focus. The following day, the pentobarbital was successfully weaned with eventual cessation of
seizures. The patient’s EEG background (red line) and clinical status gradually improved.
A. Liu et al. / Seizure 22 (2013) 893–896 895present, including clinical computer console, vital signs monitor,
bed, and pneumatic boot machine were undisturbed during rTMS.
Following rTMS, seizure frequency decreased from a total of 9
prolonged seizures in the 72 h prior to administration (20–50 min
each), to a total of one prolonged focal motor seizure (45 min)
occurring approximately 48 h after TMS administration. However,
72 h after rTMS, his seizures increased in frequency.
On day 12, VNS was again turned off in preparation for a second
round of rTMS. However, because of seizure recurrence while the
VNS was temporarily turned off and resulting alteration in
consciousness, he was unable to consent for rTMS. During the last
week of his hospital stay, his VNS settings (including output current
and duty cycle) were increased. His seizure frequency and duration
gradually returned to baseline. He was discharged after 22 days.
4. Discussion
Our two cases provide preliminary evidence of safety and
efﬁcacy of low frequency rTMS for management of focal RSE in the
ICU. Our choice of protocol in these two cases of RSE in the ICU
setting was based on our experience with epilepsia partialis
continua in the outpatient setting.7 In previous cases, low-
frequency 1 Hz stimulation has been applied at 90–100% MT over
the seizure focus, for 20–30 min. In Patient 1, the clinical team
spent signiﬁcant time setting up equipment and testing whether
TMS discharge would interfere with ICU electronics. Due to time
constraints, the team was only able to apply 1 Hz TMS for 20 min.
Furthermore, because the patient’s signiﬁcant peripheral edema
did not allow for a motor threshold to be assessed, the stimulation
intensity was applied at 70% MO.11 In this patient, rTMS applied
over the epileptogenic cortex was associated with decreased
seizure frequency, allowing pentobarbital and phenobarbital to be
weaned successfully. In the second patient, administration of rTMS
temporarily decreased the frequency of seizure activity in the ﬁrst
72 h after application. Notably, as in prior reports, rTMS did not
exacerbate seizure frequency or induce secondary generalization
in either patient.7,13 rTMS also did not interfere with ICU
equipment and monitoring.
Previous commentaries have suggested that AEDs and anes-
thetics, by altering synaptic plasticity, could decrease the efﬁcacy
of neurostimulation.7 Typically, electroconvulsive therapy (ECT)
protocols used for RSE include decreased or withdrawn AEDs and
anesthetics to allow a generalized convulsion.12 This hypothesis
has not been tested in the clinical setting with rTMS. Here, a
reduction in seizure frequency following 1 Hz rTMS in a patient
(case #1) who is intubated and sedated by a moderate-dose
pentobarbital infusion as well as multiple AEDs, suggests thatcortical plasticity can be effectively modulated by rTMS even under
barbiturate anesthesia
In a recent review and suggested treatment algorithm for
super-refractory SE, rTMS was considered to be of low potential
utility.3 In contrast, our report and another recent case10 suggest
rTMS in RSE merits further exploration. New studies should
investigate various rTMS stimulation parameters, safety issues,
and bioengineering considerations in the ICU setting.
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